News coverage about Neovasc (NASDAQ:NVCN) (TSE:NVC) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neovasc earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.1844427943102 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

Separately, Zacks Investment Research upgraded Neovasc from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Wednesday.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last posted its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.02). Neovasc had a negative net margin of 68.34% and a negative return on equity of 58.08%. The firm had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $1.40 million.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/10/13/neovasc-nvcn-receiving-somewhat-favorable-news-coverage-report-shows.html.

Neovasc Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Insider Buying and Selling by Quarter for Neovasc (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.